Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Melinta Therapeutics Inc (MLNT)

Melinta Therapeutics Inc (MLNT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,854
  • Shares Outstanding, K 13,751
  • Annual Sales, $ 96,430 K
  • Annual Income, $ -157,190 K
  • 60-Month Beta 4.54
  • Price/Sales 0.62
  • Price/Cash Flow N/A
  • Price/Book 0.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -2.38
  • Number of Estimates 2
  • High Estimate -2.29
  • Low Estimate -2.48
  • Prior Year -2.50
  • Growth Rate Est. (year over year) +4.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.96 +44.59%
on 09/20/19
4.75 -9.89%
on 10/16/19
+1.05 (+32.51%)
since 09/18/19
3-Month
2.17 +97.24%
on 09/05/19
4.75 -9.89%
on 10/16/19
+0.35 (+8.91%)
since 07/18/19
52-Week
1.62 +164.20%
on 06/14/19
19.85 -78.44%
on 10/19/18
-14.72 (-77.47%)
since 10/18/18

Most Recent Stories

More News
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies...

SMMT : 1.71 (+5.88%)
CDTX : 1.88 (-2.08%)
ETTX : 5.75 (-0.86%)
ITRM : 3.36 (-15.15%)
MLNT : 4.28 (-2.28%)
NBRV : 1.99 (-2.93%)
PRTK : 3.24 (-6.36%)
SCYX : 1.12 (-1.75%)
Implied Volatility Surging for Melinta Therapeutics (MLNT) Stock Options

Investors need to pay close attention to Melinta Therapeutics (MLNT) stock based on the movements in the options market lately.

MLNT : 4.28 (-2.28%)
Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director

Melinta Therapeutics, Inc. (Nasdaq: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer...

MLNT : 4.28 (-2.28%)
Melinta Therapeutics, Inc. (MLNT) Reports Q2 Loss, Tops Revenue Estimates

Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -19.46% and 13.96%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?...

MLNT : 4.28 (-2.28%)
Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan

Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced changes...

MLNT : 4.28 (-2.28%)
Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

~ Revenue of $16.0 million, Including Net Product Sales of $13.8 million, for the Second Quarter 2019 ~

MLNT : 4.28 (-2.28%)
Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting

~ Second Quarter 2019 Financial Results to be Reported on Friday, August 9, 2019 ~

MLNT : 4.28 (-2.28%)
Cronos (CRON) to Report Q2 Earnings: What's in the Cards?

Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when it reports second-quarter results.

TEVA : 7.50 (-3.47%)
MO : 44.33 (+0.11%)
CRON : 8.32 (-6.09%)
MLNT : 4.28 (-2.28%)
Is a Beat in Store for Melinta (MLNT) This Earnings Season?

Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.

AGN : 173.60 (+0.64%)
MDCO : 56.99 (+1.79%)
REGN : 300.19 (-0.46%)
MLNT : 4.28 (-2.28%)
Melinta Therapeutics, Inc. (MLNT) Dips More Than Broader Markets: What You Should Know

Melinta Therapeutics, Inc. (MLNT) closed at $4.07 in the latest trading session, marking a -0.49% move from the prior day.

MLNT : 4.28 (-2.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade MLNT with:

Business Summary

Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also...

See More

Key Turning Points

2nd Resistance Point 4.74
1st Resistance Point 4.51
Last Price 4.28
1st Support Level 3.95
2nd Support Level 3.62

See More

52-Week High 19.85
Fibonacci 61.8% 12.89
Fibonacci 50% 10.74
Fibonacci 38.2% 8.58
Last Price 4.28
52-Week Low 1.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar